Trevi Therapeutics, Inc.
TRVI$588M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEW HAVEN34 employees
Drugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
TRVI News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Nalbuphine ER Tablets
Prurigo Nodularis
nalbuphine HCl ER tablets 90 mg BID
Prurigo Nodularis
nalbuphine HCl ER tablets 60 mg BID
Uremic Pruritus
nalbuphine HCl ER
Uremic Pruritus
NAL ER
Refractory Chronic Cough
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nalbuphine ER Tablets | Phase 3 | Prurigo Nodularis | - | - |
nalbuphine HCl ER tablets 90 mg BID | Phase 3 | Prurigo Nodularis | - | - |
nalbuphine HCl ER tablets 60 mg BID | Phase 3 | Uremic Pruritus | - | - |
nalbuphine HCl ER | Phase 3 | Uremic Pruritus | - | - |
NAL ER | Phase 2 | Refractory Chronic Cough | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply